Publisher
Springer International Publishing
Reference58 articles.
1. Figueiredo J, Melo S, Carneiro P, Moreira A, et al. Clinical spectrum and pleiotropic nature of CDH1 germline mutations. J Med Genet. 2019;56:199–208.
2. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Genetic/ familial high-risk assessment: breast, ovarian, and pancreatic. Version 2.2022, March 9, 2022.
3. Ngeow J, Sesock K, Eng C. Breast cancer risk and clinical implications for germline PTEN mutation carriers. Breast Cancer Res Treat. 2017;165:1–8.
4. Rath MG, Masciari S, Gelman R, Miron A, et al. Prevalence of germline TP53 mutations in HER2- positive breast cancer patients. Breast Cancer Res Treat. 2013;139:193–8.
5. Sung H, Ferlay J, Siegel R, Laversanne M, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.